AbstractBACKGROUND: Clear cell renal cell carcinoma (CRCC) is the most common malignant tumor of the kidney, and the clinical outcome of CRCC is related with the metastatic potential of CRCC. A significant proportion of metastatic CRCC remains incurable. Recently, immunotherapy against specific targets such as programmed death 1 (PD1) has been adapted for fatal cases of CRCC. MATERIALS AND METHODS: In this study, we aimed to evaluate the potential of tumor-infiltrating PD1-positive lymphocytes or FoxP3-positive regulatory T cells (Tregs) as predictors of the metastatic potential or prognosis of CRCC and investigate possible correlations with Epstein-Barr virus (EBV) infection in 199 cases of CRCC. RESULTS: PD1 positivity, high Treg number, ...
Background: It has been hypothesized that M2 macrophages and regulatory T cells (Tregs) may contribu...
Background: Surgery is the standard treatment in localized renal cell carcinoma (RCC). Pembrolizumab...
Background: The Meet-URO 18 study is ongoing to assess the prognostic role of I-TME in advanced RCC ...
AbstractBACKGROUND: Clear cell renal cell carcinoma (CRCC) is the most common malignant tumor of the...
Clear cell renal cell carcinoma (ccRCC) has a high metastatic rate, and its incidence and mortality ...
Jiaxi Yao,* Wei Xi,* Yanjun Zhu, Hang Wang, Xiaoyi Hu, Jianming Guo Department of Urology, Zhongshan...
BackgroundModulation of programmed cell death in tumor cells alters the tumor microenvironment and t...
BackgroundModulation of programmed cell death in tumor cells alters the tumor microenvironment and t...
Background. Immunity exerts momentous functions in the progression and treatment of kidney renal cle...
BackgroundModulation of programmed cell death in tumor cells alters the tumor microenvironment and t...
BackgroundKidney Renal Clear Cell Carcinoma (KIRC) is one of the most prevalent types of cancer worl...
Immune status affects the initiation and progression of clear cell renal cell carcinoma (ccRCC), the...
Purpose Checkpoint therapy is now the cornerstone of treatment for patients with renal cell carcinom...
Programmed death ligand 1 (PD-L1) is a protein which, when interacting with its receptor programmed ...
BackgroundIncreasing evidence has elucidated the clinical significance of tumor infiltrating immune ...
Background: It has been hypothesized that M2 macrophages and regulatory T cells (Tregs) may contribu...
Background: Surgery is the standard treatment in localized renal cell carcinoma (RCC). Pembrolizumab...
Background: The Meet-URO 18 study is ongoing to assess the prognostic role of I-TME in advanced RCC ...
AbstractBACKGROUND: Clear cell renal cell carcinoma (CRCC) is the most common malignant tumor of the...
Clear cell renal cell carcinoma (ccRCC) has a high metastatic rate, and its incidence and mortality ...
Jiaxi Yao,* Wei Xi,* Yanjun Zhu, Hang Wang, Xiaoyi Hu, Jianming Guo Department of Urology, Zhongshan...
BackgroundModulation of programmed cell death in tumor cells alters the tumor microenvironment and t...
BackgroundModulation of programmed cell death in tumor cells alters the tumor microenvironment and t...
Background. Immunity exerts momentous functions in the progression and treatment of kidney renal cle...
BackgroundModulation of programmed cell death in tumor cells alters the tumor microenvironment and t...
BackgroundKidney Renal Clear Cell Carcinoma (KIRC) is one of the most prevalent types of cancer worl...
Immune status affects the initiation and progression of clear cell renal cell carcinoma (ccRCC), the...
Purpose Checkpoint therapy is now the cornerstone of treatment for patients with renal cell carcinom...
Programmed death ligand 1 (PD-L1) is a protein which, when interacting with its receptor programmed ...
BackgroundIncreasing evidence has elucidated the clinical significance of tumor infiltrating immune ...
Background: It has been hypothesized that M2 macrophages and regulatory T cells (Tregs) may contribu...
Background: Surgery is the standard treatment in localized renal cell carcinoma (RCC). Pembrolizumab...
Background: The Meet-URO 18 study is ongoing to assess the prognostic role of I-TME in advanced RCC ...